TERAPI3.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: AT09 technology. (Q2866989): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
(Removed claim: co-financing rate (P837): 76.0 percent, Removing co-finance rate from projects in portugal) |
||||||
| Property / co-financing rate | |||||||
| |||||||
| Property / co-financing rate: 76.0 percent / rank | |||||||
Revision as of 10:34, 13 September 2021
Project Q2866989 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | TERAPI3.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: AT09 technology. |
Project Q2866989 in Portugal |
Statements
25,000.0 Euro
0 references
15 December 2017
0 references
14 December 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
40°21'55.76"N, 8°39'29.95"W
0 references
O projeto TERAPI3 visa a proteção dos direitos de Propriedade Intelectual de uma nova classe de agentes terapêuticos contra doenças raras, nomeadamente doenças amiloides de transtirretina. Estes novos compostos são pequenas moléculas pertencentes à série química AT09 desenvolvida pela BSIM2. (Portuguese)
0 references
The TERAPI3 project aims to protect the intellectual property rights of a new class of therapeutic agents against rare diseases, namely transthyretin amyloid diseases. These new compounds are small molecules belonging to the AT09 chemical series developed by BSIM2. (English)
7 July 2021
0 references
Cantanhede
0 references
Identifiers
CENTRO-01-0247-FEDER-037867
0 references